Call for postdoctoral fellows in Molecular Medicine, Nordic EMBL Partnership for Molecular Medicine job in Helsinki, Finland with Nordic EMBL Partnership for Molecular Medicine. Apply Today.
(Mirror Daily, United States) – Two new studies have found that a groundbreaking DNA-editing technology called CRISPR-Cas9 could boost cancer risk in patients that use the tech to get rid of hereditary diseases.
Researchers explained that the CRISPR tool can become cancer-causing when it is used to replace unhealthy genes with healthier ones.
Two separate studies, one funded by Novartis and another one conducted by Sweden-based Karolinska Institutets, show that, during a CRISPR-Cas9 edit, the tweaked cells no longer have a cancer-suppressing protein dubbed p53, which can boost cancer risk.
P53 protects cells from cancer and lowers gene-editing methods’ success rate. The protein is essential in keeping cancer at bay, but when researchers use CRISPR-Cas9 to get rid of some inherited conditions, p53 can make cells self-destruct.